Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2018 Filed Feb 7, 2018 23:07 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Tax withholdingCommon Stock | 1,314 | $82.48 | $108,378.72 |
DisclosureSEC source: 0001209191-18-008217 · doc4.xml · nonDerivative · entry 2 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,318 F3 · kind: Payment of tax liability by withholding 1,314 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,336) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
Tax withholdingCommon Stock | 787 | $82.48 | $64,911.76 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,062 F5 · kind: Payment of tax liability by withholding 787 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,488) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 100,000 | $5.76 Strike: $5.76 | $576,000.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,832 Underlying: Common Stock · 100,000 shares Expires 2021-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Represents option of which 1/4th of the shares underlying the option becomes vested and exercisable on August 25, 2011 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 4,091 | $82.48 | $337,425.68 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · nonDerivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,033 F7 · kind: Payment of tax liability by withholding 4,091 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (4,159) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 100,000 | $80.07 | $8,006,620.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,874 F5 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 100,000 | $5.76 | $576,000.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
Tax withholdingCommon Stock | 528 | $82.48 | $43,549.44 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,942 F5 · kind: Payment of tax liability by withholding 528 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (997) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
Tax withholdingCommon Stock | 917 | $82.48 | $75,634.16 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,997 F5 · kind: Payment of tax liability by withholding 917 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,733) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:00 UTC |
BENEVICH ERICChief Commercial Officer
|
Tax withholdingCommon Stock | 917 | $82.48 | $75,634.16 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310 F3 · kind: Payment of tax liability by withholding 917 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,733) maintained by the Reporting Person. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
Tax withholdingCommon Stock | 658 | $82.48 | $54,271.84 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,446 F5 · kind: Payment of tax liability by withholding 658 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,242) maintained by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 18,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008221 · doc4.xml · derivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2020-02-05 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:09 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008221 · doc4.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC |
LYONS GARY ADirector
|
SaleCommon Stock | 5,000 | $83.08 | $415,380.00 |
DisclosureSEC source: 0001209191-18-008218 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,066 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.52 to $84.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC |
OBrien Christopher FlintFormer Chief Medical Officer
|
GrantStock Option · Derivative | 9,250 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · derivative · entry 4 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2028-02-05 F5 · derivative.exercise_date: Represents option of which 1/24th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/24th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC |
OBrien Christopher FlintFormer Chief Medical Officer
|
SaleCommon Stock | 1,113 | $83.40 | $92,819.41 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · nonDerivative · entry 2 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,310 F3 · kind: Sale of 1,113 shares of common stock issued upon vesting of restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,087) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:08 UTC |
OBrien Christopher FlintFormer Chief Medical Officer
|
SaleCommon Stock | 1,500 | $83.01 | $124,522.05 |
DisclosureSEC source: 0001209191-18-008219 · doc4.xml · nonDerivative · entry 1 OBrien Christopher Flint · CIK 0001343124 · Former Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,223 F1 · kind: Sale of 1,500 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,500) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008217 · doc4.xml · derivative · entry 5 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F7 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 6,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008217 · doc4.xml · derivative · entry 4 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Underlying: Common Stock · 6,150 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantStock Options · Derivative | 34,750 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008217 · doc4.xml · derivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,750 Underlying: Common Stock · 34,750 shares Expires 2028-02-05 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 960 | $83.19 | $79,862.59 |
DisclosureSEC source: 0001209191-18-008217 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,982 F1 · kind: Sale of 960 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (965) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 8 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F10 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 7 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 26,050 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 6 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,050 Underlying: Common Stock · 26,050 shares Expires 2028-02-05 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 1,979 | $18.15 Strike: $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Common Stock · 1,979 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 758 | $83.13 | $63,012.16 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,574 F3 · kind: Sale of 758 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,417) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.64. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,979 | $83.11 | $164,482.21 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.20 to $84.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 1,979 | $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 18,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · derivative · entry 9 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires 2021-03-15 F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F12 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 18,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · derivative · entry 8 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,400 Underlying: Common Stock · 18,400 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 104,200 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · derivative · entry 7 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,200 Underlying: Common Stock · 104,200 shares Expires 2028-02-05 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,858 | $83.47 | $238,542.97 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,874 F3 · kind: Sale of 2,858 shares of common stock issued upon vesting of 5,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (2,892) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,125 | $83.08 | $259,620.94 |
DisclosureSEC source: 0001209191-18-008211 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,482 F1 · kind: Sale of 3,125 shares of common stock issued upon vesting of 6,250 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (3,125) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.20 to $84.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · derivative · entry 6 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantRestricted Stock Unit · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantStock Option · Derivative | 26,050 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · derivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,050 Underlying: Common Stock · 26,050 shares Expires 2028-02-05 F6 · derivative.exercise_date: Represents option of which 1/48th March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 671 | $83.23 | $55,846.06 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,945 F3 · kind: Sale of 671 shares of common stock issued upon vesting of 1,925 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,254) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,375 | $83.02 | $114,151.26 |
DisclosureSEC source: 0001209191-18-008212 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,691 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.80 to $84.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantRestricted Stock Unit · Derivative | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350 Underlying: Common Stock · 5,350 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantStock Option · Derivative | 30,400 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · derivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 Underlying: Common Stock · 30,400 shares Expires 2028-02-05 F6 · derivative.exercise_date: Represents option of which 1/48th March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 887 | $83.23 | $73,821.28 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,264 F3 · kind: Sale of 887 shares of common stock issued upon vesting of 3,000 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,663) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.98 to $84.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:05 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,375 | $83.02 | $114,155.25 |
DisclosureSEC source: 0001209191-18-008209 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,601 F1 · kind: Sale of 1,375 shares of common stock issued upon vesting of 2,750 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,375) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.80 to $84.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F7 · derivative.exercise_date: A portion of this Performance based Restricted Stock Units ("PRSU") will vest upon FDA approval of opicapone within a specified time period, and portions of this PRSU will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 6,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,150 Underlying: Common Stock · 6,150 shares Expires not disclosed F5 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F6 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 34,750 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · derivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,750 Underlying: Common Stock · 34,750 shares Expires 2028-02-05 F4 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:00 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 820 | $83.14 | $68,174.23 |
DisclosureSEC source: 0001209191-18-008206 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,577 F1 · kind: Sale of 820 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,355) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.98 to $84.41. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008205 · doc4.xml · derivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2020-02-05 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F3 · derivative.exercise_date: Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008205 · doc4.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F2 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 7 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:59 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008204 · doc4.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.